Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable ...
Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive ...
Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalInitiation of the ...
Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in ...
Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 ...
EXCLUSIVE: The new CBS News editor-in-chief has chartered a private plane, made last-minute logistical changes and fired off ...
There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
Cidara Therapeutics skyrockets 1,165% after positive CD388 data and Merck's acquisition bid. Read why CDTX stock is a Hold.
Florida's Space Coast saw major developments in 2025, including 109 rocket launches and significant expansion at Port ...
Uber utilizes a massive scale of 9.4 million drivers and 200 million users to create a compounding network effect that drives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback